Home Search

abvc - search results

If you're not happy with the results, please do another search

ABVC BioPharma (ABVC) up 160% on News

And the Day-Traders Say, I'll Drink to That! LIVE QUOTE

ABVC BioPharma (ABVC) Approved for ABV-1505 Phase II Part II in Taiwan Sites

Gentleman, Start Your Engines? ABVC BioPharma Receives Taiwan Regulatory Approval for ABV-1505 ADHD Phase II Part 2 Clinical Study
American BriVision

American BriVision’s (ABVC) Clinical Study Sparks Interest From Potential Partners.

Is Wall Street Missing American Brivision's Full Clinical Safety and Efficacy Study? We Think it has. Potential...

American BriVision’s (ABVC) Novel Polygala Plant Extract, for the Treatment of Clinical Depression.

American BriVision Announces New Patent Filed for Treatment of Major Depressive Disorder. Phase II clinical study completed at...
American Brivision, Biotech Stock Review

American BriVision (ABVC) Reports Completion Clinical Trial for Treatment of Adult ADHD.

American BriVision (ABVC) Reports Completion of ABV-1505 Phase II Part I Clinical Trial for Treatment of Adult ADHD. Last...
American Brivision

Adding American BriVision (ABVC) $3.30 to Stocks We Expect Double List. $7.00 Price Potential.

Adding to Our 2020 Biotech 5-Pack, 5 Stocks We Expect to Double in 2020
Immunomedics, Biotech Stock Review

Immunomedics (IMMU) $33 | Raising Price Potential to $60. American BriVision (ABVC) $3.00 |...

We Are Raising the Price Potential of Immunomedics (IMMU) to $60, Highest on the Street, and Initiating Coverage on Another $3.00 Medical...
American BriVision

American BriVision (ABVC) Improves Working Capital and Reduce Debt.

American BriVision Announces Two Financial Transactions to Improve Working Capital and Reduce Debt FREMONT, CA, April 13, 2020...
America BriVision, Biotech Stock Review

Adding American BriVision (ABVC) $2.00 to Watch List.

New client and an incubator, studying now. Thinly, thinly traded. We like what we've read so far about their vitreous substitute (eyeball...

Adding Immix Biopharma (IMMX) to 2022 Biotech 12 Pack List.

Added to 12 Biotech Stocks we Expect to Double List. The Original Biotech 6-Pack from 2020, is Growing to...

Latest article

Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!

Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.

CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...